Incidence, Severity and Clinical Correlation of Oxaliplatin Induced Neuropathy in Patients with Colorectal Cancer: A Single Institutional Experience.
Autor: | Mallik, Sreya, Roy, Partha Sarathi, Saikia, Bhargab Jyoti, Hazarika, Munlima, Talukdar, Abhijit |
---|---|
Předmět: |
TREATMENT of peripheral neuropathy
PERIPHERAL neuropathy DRUG toxicity PATIENT compliance ADENOCARCINOMA RISK assessment MAGNESIUM PALLIATIVE treatment ANTIMETABOLITES SCIENTIFIC observation FISHER exact test CANCER patient medical care COLORECTAL cancer SEVERITY of illness index CANCER patients DESCRIPTIVE statistics CHI-squared test METASTASIS LONGITUDINAL method ADJUVANT chemotherapy CALCIUM ODDS ratio OXALIPLATIN QUALITY of life FOLINIC acid DEVELOPING countries PARESTHESIA TUMOR classification DATA analysis software ACTIVITIES of daily living DISEASE incidence |
Zdroj: | Asian Pacific Journal of Cancer Care; 2024, Vol. 9 Issue 1, p55-63, 9p |
Abstrakt: | Colorectal cancer is the third most commonly diagnosed cancer worldwide, and its incidence is increasing in developing countries. Chemotherapy plays a significant role in the treatment of locally advanced and metastatic colorectal cancer. Oxaliplatin has remained the backbone of the treatment of colorectal carcinoma. The primary dose-limiting toxicity of oxaliplatin is neuropathy, which can reduce compliance during therapy and impair daily living activities. With limited data regarding the occurrence of oxaliplatin-induced peripheral neuropathy (OIPN) in the Indian population, we aimed to determine the incidence and severity of oxaliplatin-induced neurotoxicity and its clinical correlation with various clinical parameters in patients with colorectal carcinoma in a cancer care centre from North-East India. Material and Methods: A prospective observational analysis was performed on all histologically confirmed cases of colorectal adenocarcinoma who received oxaliplatin-based chemotherapy either in an adjuvant setting or first-line palliative setting at Dr. B. Borooah Cancer Institute between April 2019 to March 2020. Results: Our study evaluated 76 patients with colorectal carcinoma with a mean age of 54.07 ± 10 years. The majority (65.8%) of the patients had adenocarcinoma of the colon, and 34.2% had rectal adenocarcinoma. Twenty-three (30.3%) patients presented with metastatic disease. Oxaliplatin-based chemotherapy regimens were either CAPOX (72.4%) or FOLFOX (27.6%). Acute OIPN was observed in 59 patients (77.6%), and the most common symptom was cold-induced perioral paraesthesia. The most frequent grade for acute OIPN was grade II (30.3%). Chronic OIPN was seen in 47 (61.8%) patients, with the majority developing grade II neuropathy and was manifested mainly after 4th cycle of chemotherapy. The incidence of OIPN was higher in the patients aged ≥60 years, with a cumulative oxaliplatin dose of > 1000 mg/m² and baseline low serum magnesium or calcium level. Conclusion: Oxaliplatin is one of the essential chemotherapy drugs used in colorectal cancer with significant dose-limiting toxicity of peripheral neuropathy. Well-timed identification of neuropathic symptoms can increase treatment adherence and improve the patient's quality of life. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |